Mirjam, a pharmacometrics consultant, serves as the US Lead for Pharmacometrics, Division II, at Certara. She brings more than 18 years of experience in clinical pharmacology, pharmacometrics, and systems pharmacology across a range of therapeutic modalities, with specialized expertise in Cell and Gene Therapy and Targeted Radionuclide Therapy (TRT). Prior to joining Certara in 2022, Mirjam spent more than five years focused on advancing quantitative strategies for TRT and cell and gene therapy programs.